AML NOS prognostic list

Differential
Counter

Flow
Tutorial

Myeloproliferative neoplasms	Neoplasms with eosinophilia (PDGRA/PDGFRB/FGFR1)	MDS/MPN	MDS	AML	Acute leukemia ambiguous lineage
Precursor lymphoid neoplasms	Mature B cell neoplasms	Mature T and NK neoplasms	Hodgkin lymphoma	Immunodeficiency associated lymphoproliferative disorders	Histiocytic and dendritic cell neoplasms

Acute Myeloid Leukemia, Not Otherwise Specified
	Unusual antigen expression abstracts	Prognostic abstracts	Cytogenetic abstracts	Antigen chart

AML with recurrent genetic abnormalities

AML with myelodyspasia related changes

Therapy related myeloid neoplasms

Myeloid sarcoma

Myeloid proliferations related to Down's Syndrome

Blastic plasmacytoid dendritic cell neoplasm

Article	Notes
Favorable Prognosis
Nucleophosmin
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biological and clinical features.
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
CCAAT Enhancer Binding Protein Alpha (CEBPA) mutations
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.
Multiple gene studies
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Risk-stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and expression markers.	FLT3, NPM1, N-RAS, K-RAS, IDH1, IDH2 and CEBPA(DM/SM) (double/single)
Unfavorable Prognosis
FMS-like tyrosine kinase 3 (FLT3)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
Multiple gene studies
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Risk-stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and expression markers.	FLT3, NPM1, N-RAS, K-RAS, IDH1, IDH2 and CEBPA(DM/SM) (double/single)